Elevated hemoglobin occurs when red blood cell production increases or blood volume decreases, leading to higher concentrations of the oxygen-carrying protein in the bloodstream. This condition may result from physiological adaptations, underlying diseases, or external factors such as smoking or living at high altitudes.
Hemoglobin is produced in the bone marrow under the influence of erythropoietin, a hormone released by the kidneys in response to low oxygen levels. When oxygen delivery is compromised, the body compensates by making more red blood cells to carry more oxygen. This mechanism is normal in high-altitude environments, where lower atmospheric pressure reduces oxygen availability. For example, residents of cities above 2,500 meters (8,200 feet), such as La Paz, Bolivia, often have hemoglobin levels above 16 g/dL in women and 17 g/dL in men due to sustained hypoxic stimulation.
Chronic hypoxia from lung disease or heart failure can also trigger increased hemoglobin. A 2021 study published in Chest found that patients with moderate to severe COPD had average hemoglobin levels 1.5 g/dL higher than healthy controls, reflecting long-term compensation for reduced oxygen exchange in the lungs.
Primary polycythemia vera is a rare blood disorder caused by a mutation in the JAK2 gene, leading to uncontrolled red blood cell production. It affects about 2 out of every 10,000 people, according to the National Institutes of Health (NIH). Without treatment, this condition increases the risk of blood clots, stroke, and progression to leukemia.
Secondary polycythemia results from external stimuli that mimic hypoxia. Common causes include chronic obstructive pulmonary disease (COPD), sleep apnea, and congenital heart defects. A 2019 study in The American Journal of Medicine reported that 34% of patients with severe obstructive sleep apnea had hemoglobin levels exceeding 16 g/dL in women and 17 g/dL in men.
Other secondary causes include renal tumors that secrete excess erythropoietin, certain cancers, and use of performance-enhancing drugs like erythropoietin (EPO) in sports. The World Anti-Doping Agency (WADA) tracks EPO misuse because it artificially raises hemoglobin and increases the risk of cardiovascular events.
| Type | Key Cause | Typical Hemoglobin Range | Associated Risk |
|---|---|---|---|
| Primary (polycythemia vera) | JAK2 mutation | 18-22 g/dL | Thrombosis, bleeding, transformation to leukemia |
| Secondary (hypoxia-driven) | High altitude, COPD, sleep apnea | 16-20 g/dL | Increased blood viscosity, stroke |
| Relative (dehydration) | Reduced plasma volume | 15-18 g/dL | False elevation; resolves with hydration |
Smoking is a well-documented contributor to elevated hemoglobin. Carbon monoxide in cigarette smoke binds to hemoglobin with greater affinity than oxygen, reducing oxygen delivery. The body responds by producing more red blood cells to maintain tissue oxygenation. A 2020 analysis in Respiratory Research showed smokers had hemoglobin levels 0.8 g/dL higher on average than non-smokers after adjusting for age and sex.
Dehydration can falsely improve hemoglobin readings. When fluid intake drops, plasma volume decreases, concentrating red blood cells. This is known as relative polycythemia. A patient with mild dehydration may show a hemoglobin level of 17 g/dL, which normalizes after rehydration. This effect is particularly common in elderly individuals during heatwaves.
A common misconception is that high hemoglobin always indicates a serious illness. In reality, mild elevations can be benign. For example, a 45-year-old man with a hemoglobin of 17.5 g/dL who lives at 2,000 meters and exercises regularly may have no pathology. His values were stable over two years, and he had no symptoms. Only when levels exceed 18.5 g/dL in men or 17.5 g/dL in women does clinical concern arise.
High hemoglobin is frequently confused with high hematocrit, but they are not interchangeable. Hematocrit measures the percentage of blood volume occupied by red blood cells, while hemoglobin measures the amount of oxygen-carrying protein. A person can have a normal hematocrit but elevated hemoglobin due to abnormal hemoglobin variants, such as hemoglobin S in sickle cell trait.
Another frequent mix-up is equating high hemoglobin with high platelets. Platelets are involved in clotting, not oxygen transport. Elevated platelets (thrombocytosis) can occur independently or alongside high hemoglobin in myeloproliferative disorders. For example, a patient with polycythemia vera may have both high hemoglobin and high platelets. To assess this, clinicians use a complete blood count (CBC) with differential and peripheral smear review.
I once reviewed a case where a 52-year-old woman presented with fatigue and headaches. Her CBC showed hemoglobin at 19.2 g/dL and platelets at 550,000/μL. Initial suspicion was polycythemia vera. However, her JAK2 mutation test was negative. Further testing revealed her elevated platelets were due to chronic inflammation from untreated rheumatoid arthritis. Her hemoglobin normalized after treating the underlying condition, highlighting the importance of differential diagnosis.
Levels above 18.5 g/dL in men or 17.5 g/dL in women warrant investigation. The American Society of Hematology recommends evaluating persistent elevations with a physical exam, family history, and additional tests including erythropoietin levels, JAK2 mutation testing, and imaging for kidney or liver tumors.
For those with mild elevations due to lifestyle factors, such as smoking or dehydration, correcting the root cause often reverses the trend. Quitting smoking can reduce hemoglobin by 0.5-1.0 g/dL within six months. Rehydration restores plasma volume and lowers apparent hemoglobin concentration.